uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.
We are advancing a focused pipeline of innovative gene therapies. We are currently conducting a pivotal phase 3 trial in our lead indication, hemophilia B, and will initiate a Phase I/II trial in Huntington’s disease in the second half of 2019. Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.
Tuesday 26 November is the festive finale of the Amsterdam Science & Innovation Award 2019! Please find below the details for the program and location. Amsterdam Science & Innovation Award The Amsterdam Science & Innovation Award is the annual award for the most innovative research-based idea with a social and/ or commercial application. During the festive […]News
Finalists Reinout Bem and Imran Avci were interviewed by Karlijn Meinders in BNR’s broadcast Wetenschap Vandaag during Spitsuur. To listen to the interview click here.News
The Amsterdam Science & Innovation Awards go to innovations in 3D-printed embryo models, following criminal money through bank data and tackling the phosphate challenge. The Impact Awards go to Jaap Bonjer, Erwin Peterman and Gijs Wuite, and Roeland van Geuns Marissa de Boer (UvA), Jill Coster van Voorhout (UvA) and Bernadette de Bakker (Amsterdam UMC), […]News